This session highlights the latest innovations in structural and valvular cardiology, featuring novel technologies such as a new self-expandable transcatheter aortic valve for aortic stenosis treatment and a temporary atrioventricular sequential pacing system. It also discusses non-clinical testing methodologies supporting U.S. market approvals, non-invasive ultrasound therapy...

Discover cutting-edge innovations in vascular therapies highlighting novel technologies such as Pulse Intravascular Lithotripsy (IVL) for calcium modification and Amplitude Vascular Systems. The session also presents drug-free restenosis control strategies via CD31 camouflage coating promoting physiological-grade healing, emphasizing emerging solutions aimed at improving vascular intervention outcomes.

This session provides a comprehensive guide to large-bore venous access and vessel closure techniques, emphasizing best practices and the advantages of ultrasound-guided suture mediated vessel closure compared to traditional figure-of-eight suture methods. It also addresses strategies to avoid and manage potential complications encountered during these procedures.

Examine diverse clinical scenarios and management strategies for aortic paravalvular leaks (PVL), including complex percutaneous closures post-TAVI and surgical interventions. This session presents challenging cases demonstrating varied presentations and approaches such as mechanical valve loop utilization, highlighting the complexities and tailored solutions required for successful PVL...

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...